Gilead Sciences

Open: 73.0 Close: 71.58 Change: -1.42

Stop reading the whole internet to decide if you want to invest in Gilead Sciences Company Inc.

Are looking for the most relevant information about Gilead Sciences? Investor spend a lot of time searching for information to make investment decisions in Gilead Sciences. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, company, disease, buy, CymaBay, liver, and the most common words in the summary are: gilead, science, best, stock, news, inc, cymabay, . One of the sentences in the summary was: Food and Drug Administration has put a hold on trials testing …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences is buying CymaBay Therapeutics for $4.3 billion. Food and Drug Administration has put a hold on trials testing Gileads blood cancer drug Trodelvy. FDA has put hold on clinical trials testing the drug.

Today's News

gilead sciences ‘strengthens commitment to inflammatory disease with new research site. Gilead Sciences has been named one of one Newsweek Greatest Workplaces for Diversity. Gilead Sciences is buying CymaBay Therapeutics for $4.3 billion. The company is buying the developer of medicine for liver and other chronic diseases. Gilead Sciences Inc. is known for its innovative therapies in areas such as HIV, oncology, and liver diseases. Food and Drug Administration (FDA) has put a hold on trials testing Gileads blood cancer drug Trodelvy. The report will provide a comprehensive analysis of the companys financial performance and recent news developments. Gilead Sciences has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences has agreed to acquire CymaBay Therapeutics for $4.3 billion. CymaBays lead candidate seladelpar indicated to treat primary biliary cholangitis (PBC) Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, develops and commercializes innovative therapeutics in areas of unmet medical need. The company is in the Health Care sector and Biotechnology industry.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

The game is changing. There is a new strategy to evaluate Gilead Sciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, company, disease, buy, CymaBay, liver, and the most common words in the summary are: gilead, science, best, stock, news, inc, cymabay, . One of the sentences in the summary was: Food and Drug Administration has put a hold on trials testing Gileads blood cancer drug Trodelvy. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #best #stock #news #inc #cymabay.